CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free ...
Daily5h
AstraZeneca Tagrisso recommended for approval in EU by CHMP for patients with unresectable EGFR mutated lung cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion ...
InflaRx initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of InflaRx (IFRX) with a Buy rating and $10 price target InflaRx leverages its expertise in the complement ...
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...
EuropaWire12h
AstraZeneca’s Tagrisso Receives EU Recommendation as First Targeted Therapy for Unresectable EGFR-Mutated Lung Cancer
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...
Le Lézard13h
LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab
Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting and if approved catumaxomab will be the only approved drug for ...
Armed robbery in Revesby14h
Pharmanovia, Lindis Ink Deal on Catumaxomab for Ascites
Catumaxomab Received a Positive Opinion From the EMA's Committee for Medicinal Products for Human Use (CHMP) at Its October 2024 Meeting and If ...
Mena FN18h
Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech To Commercialise Catumaxomab For Treatment O...
Catumaxomab received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting with EU marketing authorization ...